Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
BXRXQ similar filings
- 28 Feb 24 Bankruptcy or Receivership
- 12 Dec 23 Other Events
- 15 Nov 23 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
- 25 Oct 23 Changes in Registrant's Certifying Accountant
- 13 Oct 23 Submission of Matters to a Vote of Security Holders
- 6 Oct 23 Departure of Directors or Certain Officers
- 29 Sep 23 Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
Filing view
External links
Exhibit 16.1
October 25, 2023
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen:
We have read Item 4.01 of Form 8-K dated October 25, 2023 of Baudax Bio, Inc. and are in agreement with the statements contained therein as it regards our firm. We have no basis to agree or disagree with other statements of the registrant contained in Item 4.01.
Sincerely,
/s/ EisnerAmper LLP
EisnerAmper LLP